ZTS Stock Recent News
ZTS LATEST HEADLINES
Zoetis (ZTS -8.79%), the leader in animal health solutions, released its fourth quarter results for 2024 on Feb. 13. The company reported an adjusted earnings per share (EPS) of $1.40, which exceeded the consensus estimate of $1.36.
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zoetis (ZTS) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.24 per share a year ago.
Animal healthcare company Zoetis forecast annual profit and revenue below Wall Street estimates on Thursday, partly due to a hit from a stronger dollar, sending its shares down 9% in premarket trading.
Phibro Animal Health delivers animal health and nutritional solutions through feed additives, vaccines, and performance products. The Zoetis acquisition added 37 product lines, driving a 24% increase in net sales and 64% growth in adjusted EBITDA. The company projects strong revenue growth in 2025 with expanding margins and updated EPS guidance.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2024 as well as provided full year guidance for 2025. The company reported revenue of $2.3 billion for the fourth quarter of 2024, an increase of 5% compared with the fourth quarter of 2023. On an operational1 basis, revenue for the fourth quarter of 2024 increased 6% compared with the fourth quarter of 2023. Net income for the fourth quarter of 2024 was $581 mill.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zoetis (ZTS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
There's no way around it. I'm approaching the age of 40 faster than I'd like.
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.